Amitiza (lubiprostone) / Takeda, Mallinckrodt - LARVOL DELTA

Patients' Real-World Experiences With Pharmacologic Therapies for Irritable Bowel Syndrome With Constipation: A Mixed-Methods Analysis and Classification of Social Media and E-Forum Posts. (PubMed, Neurogastroenterol Motil) - "Social media provides unique insights into IBS-C patients' real-world experiences with FDA-approved therapies. Findings highlight variability in efficacy, biopsychosocial impacts, and adherence challenges, underscoring the need for shared decision making and proactive management of barriers to optimize outcomes."

Journal • Real-world evidence • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Mood Disorders • Psychiatry

First Reported Case of MRI Performed on a Patient With Multiple Vibrant Vibrating Capsules In Situ (ACG 2026) - "She experienced ineffective responses or side-effects to multiple pharmacologic therapies including polyethylene glycol, senna, bisacodyl (oral and rectal), glycerin suppositories, magnesium salts, linaclotide, plecanatide, lubiprostone, prucalopride, and tenapanor. This report also highlights the need for improved screening for ingestible electronic devices prior to MRI. Figure: X-ray Showing 5 Vibrant Vibrating Capsules In Situ 1 Day After MRI"

Clinical • Constipation • Endocrine Disorders • Fibromyalgia • Gastroenterology • Gastrointestinal Disorder • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics

Adjunctive Use of Vibrating Capsule for Refractory Constipation in Autosomal Dominant Polycystic Kidney Disease With Severe Organomegaly (ACG 2026) - "He had failed or inadequately responded to lactulose, polyethylene glycol, magnesium citrate, bisacodyl, senna, mineral oil, enemas, suppositories, lubiprostone, prucalopride, fiber, linaclotide alone, plecanatide alone, and pelvic floor physical therapy. Figure: Figure 1b. Sagittal T2-weighted MRI demonstrates renomegaly along with stool-filled colon."

Autism Spectrum Disorder • Autosomal Dominant Polycystic Kidney Disease • Chronic Kidney Disease • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Muscular Dystrophy • Myotonic Dystrophy • Nephrology • Pancreatic Cancer • Polycystic Kidney Disease • Renal Disease

Early Physiologic Motility Testing Versus Empiric Medical Management in IBS-C: A Propensity-Matched Real-World Analysis (ACG 2026) - "Cohort 2 received empiric management (lubiprostone, linaclotide, plecanatide, tegaserod, lactulose, or PEG 3350) without motility testing. Cohorts were well-balanced post-matching (83.5% female each). Functional symptom persistence was similar (74.9% vs. 77.3%; RR 0.97, 95% CI 0.90â1.05; p=0.42; HR 0.88, 95% CI 0.76â1.03; log-rank p=0.12)."

Clinical • Real-world • Real-world evidence • CNS Disorders • Colorectal Cancer • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Mood Disorders • Type 2 Diabetes Mellitus

Comparative Real-World Safety of Linaclotide, Plecanatide, and Lubiprostone: Risks of AKI and Hemodynamic Events (ACG 2026) - "After matching, 40,131 linaclotide-plecanatide and 115,091 linaclotide-lubiprostone pairs were identified. Compared with plecanatide, linaclotide users had higher 30-day risks of AKI (0.47% vs 0.24%; RR 1.95, 95% CI 1.53-2.49, p< 0.0001), volume depletion (0.53% vs 0.40%; RR 1.32, 95% CI 1.07-1.61, p=0.008), hypotension (0.70% vs 0.59%; RR 1.20, 95% CI 1.01-1.42, p=0.04), and diarrhea (1.32% vs 1.04%; RR 1.27, 95% CI 1.11-1.44, p=0.0003). When compared with lubiprostone, linaclotide users experienced lower risks of AKI (0.59% vs 0.74%; RR 0.80, 95% CI 0.73-0.89, p< 0.0001), volume depletion (0.61% vs 0.76%; RR 0.81, 95% CI 0.73-0.89, p< 0.0001), and hypotension (0.83% vs 0.95%; RR 0.88, 95% CI 0.80-0.95, p=0.002), with similar rates of diarrhea (1.30% vs 1.30%; RR 1.00, 95% CI 0.93-1.07, p=0.94)."

Clinical • Real-world • Real-world evidence • Acute Kidney Injury • Chronic Kidney Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Hepatology • Hypotension • Nephrology • Renal Disease

Efficacy and Safety of Elobixibat for Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis (ACG 2026) - "The nausea rate of 0.2% is substantially lower than the 15-32% reported with lubiprostone. Twenty-three studies (N >9,000) were included. Elobixibat significantly increased weekly SBM by 3.04/week (95% CI 2.34-3.73; k=14; I 2 =97.7%) and improved BSFS by 1.33 points (95% CI 1.03-1.63; k=13; I 2 =95.5%). Nearly 80% (95% CI 68.1-89.5; k=6) of patients achieved SBM within 24 hours of first dose."

Retrospective data • Review • Constipation • Gastroenterology • Gastrointestinal Disorder

Pan-Enteric Dysmotility and Small Bowel Malabsorption: A Multidisciplinary Challenge in a Patient With LADA and Hashimoto's (ACG 2026) - "Despite extensive medical therapy which included prokinetics (prucalopride, erythromycin, azithromycin) , intestinal secretagogues (lubiprostone, plecanatide), antiemetics (ondansetron, prochlorperazine) and antispasmodics (dicyclomine), (proton pump inhibitors and H2 blockers), symptoms persisted . An integrated neuro-immuno-gastroenterological approach is essential in such complex presentations. Figure: Smallbowel Figure: Autoimmune"

Clinical • Constipation • Crohn's disease • Diabetes • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Secondary Hyperparathyroidism • IL13 • IL6

Beyond gluten-free diet: repurposing pitavastatin and lubiprostone as cathepsin S inhibitors for celiac disease therapy. (PubMed, In Silico Pharmacol) - "A focused screening of FDA-approved drugs identified pitavastatin and lubiprostone as promising cathepsin S inhibitors for CeD therapy. Established safety profiles and well-established pharmacokinetics are just a few of the substantial advantages these medicines offer for clinical translation."

Journal • Celiac Disease • Immunology

Advances in the Treatment of Refractory Pediatric Constipation (PubMed, Acta Gastroenterol Latinoam) - "Amongthe innovative medications, prosecretory agents like linaclotide(already approved for children over 6 years old), lubiprostone andplecanatide, wich increase intestinal secretion, stand out. Other drugs,such as prucalopride (5HT-4 agonist) and pyridostigmine, aim to improvemotility...There are therapies thathave been little explored but show promise for the future, such asvibrating capsules, magnetic neurostimulation, and mind-body approacheslike hypnosis. Specific pediatric research and an individualizedtreatment approach are crucial to optimize adherence and outcomes inthese complex patients."

Journal • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Pediatrics

Secretagogue laxatives as a potential strategy to overcome adherence barriers to over-the-counter treatment for clozapine-induced constipation. (PubMed, Ment Health Clin) - "In 4 cases, lubiprostone or linaclotide was initiated, either as monotherapy or in combination with over-the-counter laxatives. In these cases, adherence barriers to over-the-counter laxatives were identified. A secretagogue laxative was implemented, well-tolerated, and able to be continued for the duration of follow-up."

Journal • Alzheimer's Disease • Cognitive Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder

Constipation with bloating: a clinical approach to evaluation and management. (PubMed, Ann Med) - "Management approaches discussed include dietary modification, biofeedback, and pharmacologic therapy, including over-the-counter treatments, plecanatide, linaclotide, lubiprostone, tenapanor, neuromodulators, and antibiotics. There is a need for additional research to further understand the physiology of bloating. In an era when personalized medicine is becoming increasingly emphasized, understanding the pathophysiology of bloating for an individual patient, be it alongside constipation or other GI and non-GI symptoms, will be paramount to improve treatment outcomes."

Journal • Review • Constipation • Gastroenterology • Gastrointestinal Disorder

Irritable Bowel Syndrome with Constipation: Diagnosis and Multisymptom Management Beyond Abdominal Pain and Bowel Movement Frequency: A Review. (PubMed, Adv Ther) - "Several medications are indicated for IBS-C, including secretagogues such as guanylate cyclase C agonists (plecanatide, linaclotide) and chloride channel activators (lubiprostone [women only]), as well as sodium/hydrogen exchanger 3 (NHE3) inhibitors (tenapanor). An integrated approach to treatment of IBS-C, particularly in patients with persistent symptoms after treatment with first-line secretagogues or NHE3 inhibitors, may include neuromodulators, appropriate antibiotic regimens in those with intestinal methanogen overgrowth (IMO), and/or nonpharmacologic approaches including dietary interventions and brain-gut behavioral therapies. Effective treatment plans for IBS-C should target the most bothersome symptoms, including a collaborative discussion of risks/benefits of various treatments, culminating in an agreement on a path forward between the patient and healthcare provider."

Journal • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

Trends in the prescription of constipation medications in Japan (fiscal years 2019-2023): A nationwide baseline study prior to the 2023 clinical guidelines. (PubMed, Drug Discov Ther) - "Since the launch of lubiprostone in November 2012, several new agents with novel mechanisms have been introduced, and their use has increased...Magnesium oxide showed the smallest regional variation, whereas polyethylene glycol and linaclotide showed the largest variations in FY 2019 and FY 2023, respectively. Throughout the 5-year period, the highest SCRs for contact laxatives were observed in Akita, Iwate, and Aomori prefectures. Our findings provide a comprehensive nationwide picture of evolving constipation treatment patterns and regional variations in Japan, establishing baseline data for evaluating the impact of guideline dissemination and evidence accumulation on clinical practice."

Clinical guideline • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

LUBIPROSTONE IN CHRONIC KIDNEY DISEASE: INSIGHTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL (ISN-WCN 2026) - "Findings were published in August 2025 in Science Advances. Clinical Trials Registry Number: UMIN000023850."

Clinical • P2 data • Chronic Kidney Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Nephrology • Renal Disease

Laxative use and acute kidney injury risk: Analysis of a Japanese hospital-based database. (PubMed, J Pharmacol Exp Ther) - "The findings suggest that there is no difference in AKI risk among the various laxatives studied. SIGNIFICANCE STATEMENT: The results indicate that there were no differences in the risk of acute kidney injury among lubiprostone, linaclotide, senna, and magnesium oxide, suggesting that the use of these laxatives might not impact the risk of acute kidney injury."

Journal • Acute Kidney Injury • Nephrology • Renal Disease

Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=124 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P2 trial • Colon Cancer • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor

Real-World Safety Analysis of the Constipation-Predominant IBS Treatment Options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor. (PubMed, Gastroenterol Hepatol (N Y)) - No abstract available

Journal • Real-world evidence • Constipation • Gastroenterology • Gastrointestinal Disorder

Comparison of Polyethylene Glycol Combined with Lubiprostone versus Standard-Dose Polyethylene Glycol for Bowel Preparation Before Colonoscopy in Patients with Chronic Constipation: A Multicenter Randomized Controlled Trial (ChiCTR) - P=N/A | N=462 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University

New trial • Constipation • Gastroenterology • Gastrointestinal Disorder

PGE1 Suppresses the Expression of M2 Markers on Macrophages Through Prostaglandin Receptors. (PubMed, Cells) - "PGE1 decreased M2 marker expression in heterospheroids more effectively compared with PGE2, PGE3, misoprostol, and 13,14-dihydro-15-keto-PGE1, whereas the suppressive effects of 15-keto- and 13,14-dihydro-PGE1s, and lubiprostone were comparable to that of PGE1. Pharmacological inhibition of prostaglandin receptors revealed that EP2 and EP4 receptors are involved in the PGE1-induced reprogramming of M2-like macrophages to M1 macrophages. In summary, PGE1 and its derivatives are promising TAM-targeting immunotherapeutics."

Biomarker • IO biomarker • Journal • Liver Cancer • Oncology • Solid Tumor • CXCR2

STOPS 03: Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation (clinicaltrials.gov) - P3 | N=346 | Recruiting | Sponsor: Third Military Medical University

New P3 trial • Constipation • Gastroenterology • Gastrointestinal Disorder

Effect of Multiple Pharmacological Interventions and Magnetic Control on Capsule Endoscopy Gastrointestinal Transit Time and Diagnostic Yield: A Systematic Review and Meta-Analysis. (PubMed, JGH Open) - "Erythromycin and magnetic guidance were consistently associated with faster gastric passage, while lubiprostone and polyethylene glycol (PEG) shortened SBTT compared with control groups. For improving overall completion, metoclopramide remains a dependable option. These findings support individualized preparation strategies tailored to the specific diagnostic goals of CE."

Journal • Retrospective data

Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia. (PubMed, J Neurogastroenterol Motil) - "First line therapies such as dietary-fiber optimization and osmotic laxatives are widely available, but newer pharmacotherapies (prucalopride, linaclotide, lubiprostone, and elobixibat) remain costly and unevenly accessible. The Bali Chronic Constipation Roundtable highlighted Asia's need for region specific diagnostics and management. Addressing diagnostic and treatment gaps will improve outcomes, while ongoing researcher clinician policy collaboration must standardize guidelines, advance research, and ensure equitable care across Asia."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Bioelectric Reprogramming of the Bone Marrow Niche in Acute Myeloid Leukemia (ASH 2023) - "On the contrary, we treated AML-MSCs with hyperpolarizing agents (lubiprostone and ivermectin), which reverted their phenotype to that of h-MSCs, including lower proliferation level (ivermectin -1.9-fold, p<0.05), higher immunomodulatory potential, and higher CaV1.2 levels (1.8-fold by flow cytometry, p<0.05) with respect to untreated AML-MSCs, suggesting that depolarization is reversible and that by modeling MSCs Vmem we can restore an healthy stroma within the BM niche...In addition, we unveiled CaV1.2 channels as a key player in this process and postulated that rewriting the bioelectric code of the patient' AML-MSCs, through the restoration of voltage-dependent calcium channel CaV1.2 activity, could be a strategy to restore their healthy phenotype. These findings provide the biological rationale to evaluate the potential of novel MSCs gene or pharmacological therapies that could both disadvantage AML progression and restore a permissive BM niche."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • IL6

Lubiprostone in CKD: Insights into Mitochondrial Function and Polyamines from a Randomized Phase 2 Clinical Trial (KIDNEY WEEK 2025) - "Key findings of this work are under revision for publication. Clinical Trials Registry Number: UMIN000023850"

Clinical • P2 data • Chronic Kidney Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Nephrology • Renal Disease

Regulation and mechanism of chloride channels in proliferative vitreoretinopathy. (PubMed, Medicine (Baltimore)) - "By reducing the opening of chloride channels within RPE cells via drugs, PVR formation can be suppressed, which is sufficient to counteract retinal degeneration. Chloride channels may have crucial effects on RPE cell proliferation and migration. The therapeutic strategy of blocking chloride channels may be beneficial for PVR."

Journal • Ophthalmology • Retinal Disorders • TGFB1